TOPLINE: A novel, single-use on-body injector (OBI) for isatuximab in multiple myeloma is noninferior to the standard intravenous (IV) formulation in efficacy and pharmacokinetics and has no unexpected safety signals. METHODOLOGY: IRAKLIA is an ongoing study of administration methods of isatuximab as part of a triplet regimen that includes pomalidomide and dexamethasone…
Leave a Comment Leave a Comment
